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The high recurrence rate remains a major problem that strongly influenced the prognosis of hepatocellular carcinoma
(HCC) patients who received hepatectomy. The presence of microvascular invasion (MVI) is regarded as the most
important risk factor that contributes to the postoperative recurrence. Our previous study has hinted that serum
microRNA-125b (miR-125b) was associated with MVI. The aim of the present study was to identify whether serum
miR-125b can serve as a biomarker to reliably predict microvascular invasion (MVI) preoperatively. MiR-125b was
quantified in 108 HCC patients’ serum before they received surgery by quantitative real-time PCR (qRT-PCR). Our
results revealed that MVI was associated with relapse free survival (RFS) of postoperative HCC patients; surgical
margin width was associated with postoperative RFS in MVI present patients, but not in the patients without MVI.
Multivariate analysis revealed that miR-125b, tumor size and AFP were the independent predictive factors associated
with MVI in this cohort (P= .001, .001, .003, respectively). The probability of the predictive accuracy of miR-125b was
76.95% (51.32% specificity and 87.50% sensitivity), which was almost equal to the classifier established by
combination of AFP and tumor size (78.82% probability, 65.63% specificity and 84.21% sensitivity). Furthermore, the
combination of tumor size, AFP and miR-125b yielded a ROC curve area of 86.68% (72.37% specificity and 84.38%
sensitivity). Our study indicated that serummiR-125b can be used to predictMVI of HCC patients before they received
hepatic resection. Therefore, miR-125b can potentially guide individualized treatment, which helps HCC patients, with
or without MVI, to benefit from different surgical approach.
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Hepatocellular carcinoma (HCC) is the sixth most common cancer
worldwide and the second most common cause of cancer mortality. An
estimated 782,000 new liver cancer cases and 745,000 cancer deaths
occurred worldwide [1]. Liver resection (LR) and orthotopic liver
transplantation (OLT) are the best radical treatments and well perceived
as a curative treatment for HCC in cirrhotic patients with good
functional liver reserves [2]. However, the high recurrence rate of HCC
in the remnant liver, which reach an incidence of more than 20% at
1 year and 70% at 5 years [3], remains onemajor obstacle that is strongly
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undergone hepatectomy. The presence of microvascular invasion (MVI)
is regarded as the most important risk factor that is significantly
associated with recurrence within two years after surgery [4,5].
Unfortunately, MVI can currently be detected only by postoperative
histological examination, which greatly limits the usefulness for
preoperative assessment of prognosis [6], let alone when patients are
given nonsurgical treatments, such as radiofrequency ablation, ethanol
injection or transcatheter arterial chemoembolization. And, the
incidence of MVI is greater than 20% in resected HCC patients [7].
Currently, there are no effective predictors with the ability to predict
MVI effectively before hepatic resection. Certain serum factors, such as
AFP [8] and PON1 [9], have been identified as predictors of MVI
preoperatively, but the effectiveness or convenience was far from
satisfaction. Identification preoperative predictors of MVI were able to
provide satisfactory reference information for clinicians to select
appropriate surgical and/or therapeutic strategies for patients with HCC.
MicroRNAs (miRNA) are small non-coding RNAs and have crucial
functions in human diseases, including cancer. Due to its high stability
and detectability in blood plasma or serum, miRNAs constitute a novel
class of non-invasive biomarkers [10]. In recent years, there are many
studies investigating the possible ability of miRNAs serve as diagnostic or
prognostic biomarkers in human cancers, including HCC [11,12].
miR-125b has been demonstrated to suppress the proliferation and
metastasis of human liver cancer cell [13,14].However, only a few studies
have focused on identifying the predictive value of circulating miR-125b
in the serum of patients withHCC [15].Our earlier study hinted that the
expression of serum miR-125b was associated with microvascular
invasion [16], however, additional studies are needed to reaffirm. In
this study, we detected the level of miR-125b in a cohort of 108 HCC
patients’ serum in order to validate its value of predicting MVI and its
ability to serve as a biomarker. Our study suggested that preoperative
serum miR-125b can serve as a useful biomarker that helps to reliably
predict the presence of MVI before HCC patients received surgery.
Materials and Methods
Patients With HCC
One hundred eight patients withHCCwho underwent hepatectomy
from April 2012 to October 2013 were included in this study. The
including criteria were as follow: (1) did not receive any preoperative
treatment, such as ablation, TACE, radiotherapy, chemotherapy or
targeted therapy, (2) preoperative liver function was Child-Pugh A
degree, (3) treated with curative surgical liver resection (microscopically
surgical margin free of tumor), (4) intraoperative blood loss was less
than 600 ml and no intraoperative or postoperative blood transfusion,
(5) single lesion or synchronismmultiple primary lesion and no satellite
nodules were proven by postoperative pathology, (6) liver failure or
death did not happened within 30 days postoperatively.
All serum samples were collected before the patients had received
surgery at Cancer Institute and Hospital, Chinese Academy of
Medical Sciences (CAMS), between April 2012 and October 2013
and stored at −80 °C refrigerator. This study was approved by ethics
committee approval from cancer hospital CAMS, and all the
participants signed written informed consent forms.
miRNA-Specific Quantitative Real-Time RT-PCR
Serum samples from 108 HCC patients were analyzed by using
miRNA-specific quantitative real-time RT-PCR. miRNA was isolated
using a mirVana PARIS kit (Ambion). Megaplex RT reactions andpre-amplification reactions were run according to the manufacturer’s
protocol (Applied Biosystems, Foster City, CA,USA). Let-7dwas used as
an internal control for normalization [17]. Real-time PCRwas performed
using the StepOne Plus Real-time system (Applied Biosystems, Foster
City, CA, USA) and fold changes in gene expression were calculated
using the 2-ΔΔCt method [18]. The mean miRNA level from three
real-time quantitative PCR experiments was calculated for each case.
Follow-Up
Patients were followed-up at 3-month intervals for the first 2 years
and at 6-month intervals thereafter. During the follow-up visit,
alpha-fetoprotein (AFP), liver function, chest x-ray, enhanced
computed tomography (CT) and/or enhanced magnetic resonance
imaging (MRI) were performed. If inner-hepatic-recurrence was
suspected, the lesion was confirmed by hepatic digital subtraction
angiography (DSA) and/or contrast-enhanced ultrasound (CEUS).
The recurrence status was determined as described before [16].
Relapse free survival was defined as the time interval from the date of
surgery to the time of initially detected recurrence/progression or
censored on the last follow-up. The last follow-up was May 2015.
Until then, 55 patients developed recurrence.
Survival Analysis
Based onMVI and surgicalmarginwidth, theKaplan-Meier estimator
was used to calculate the median survival time of the relapse free survival
(RFS) and to describe the survival curve. A comparison of survival
analysis was performed and the P value was calculated by the log-rank
test. According to pathologically proven MVI status, the patients were
divided into 2 groups: MVI present group and MVI absent group. The
surgical margin was divided into the following 2 categories as the
subgroups: wide surgical margin group (WSM group) with a negative
surgical margin historically measured as greater more than 10 mm in
width, narrow surgical margin group (NSM group) with a negative
surgical margin historically measured less than 10 mm in width.
Statistical Analysis
SPSS 19.0 software was used for the statistical analysis. The P value
was bilaterally tested, and values less than 0.05 were regarded as
statistically significant. The patients were divided into groups based on
the median values of continuous variables or discrete variables. The
significance of differences between each pair of groups that created was
assessed by the chi-square test and fisher exact test. Student t test was
used to compare the continuous variables. Univariate and multivariate
logistic regression analysis were done to evaluate the association of the
miRNA signature and clinicopathological data to MVI, respectively.
The P values were calculated using the Wald test.
Logistic regression analysis was performed to analyze various
combinations of clinical parameters and miR-125b. Using the
independent predictors of MVI according to multivariate analysis,
the receiver operating characteristic (ROC) curves were created and
the area under the curve (AUC) was used to determine the feasibility.
The Youden’s Index was used to identify the optimal cut-off point. As
defined, the corresponding sensitivity and specificity was showed.
Results
The Level of Serum miR-125b was Correlates With MVI and
Envelop Invasion in 108 HCC Patients
We divided the 108 patients into two groups based on the median
value of the expression level of miR-125b. As shown in Table 1, low
Table 1. Correlation Between the Level of Serum miR-125b and Clinicopathologic Features in 108
HCC Patients Underwent Hepatectomy
All Cases miR-125b Expression Level P Value
Low Expression (n = 54) High Expression (n = 54)
Age
≥60 38 21 17 .420
b60 70 33 37
Gender
Male 89 45 44 .800
Female 19 9 10
Tumor size
≥5cm 43 24 18 .236
b5cm 66 30 36
Tumor multiplicity
Single 97 49 48 .750
Multiple 11 5 6
MVI
Present 32 23 9 .003
Absent 76 31 45
Envelope invasion
Present 63 38 25 .011
Absent 45 16 29
Histological grade
Well 14 5 9 .396
Moderate 78 42 36
Poorly 16 7 9
BCLC
A 72 33 39 .221
B 36 21 15
Viral hepatitis
Negative 4 1 3 .435
HBV 98 49 49
HCV 6 4 2
Cirrhosis
Present 91 48 43 .186
Absent 17 6 11
AFP (ng/ml)
≥400 25 12 13 .820
b400 83 42 41
GGT (U/ml)
≥55 49 21 28 .176
b55 59 33 26
Table 2. Correlation Between MVI and Clinicopathologic Features in 108 HCC Patients
Underwent Hepatectomy
MVI Present (n=32) MVI Absent (n=76) P Value
Age (years) 53.88±11.69 53.64±11.26 .924
Gender (Male/Female) 26/6 63/13 .838
Tumor size (cm) 6.53±3.92 3.93±2.10 .001
Tumor multiplicity (Single/Multiple) 29/3 68/8 1.000
Envelope invasion (Present/Absent) 26/6 37/39 .002
Differentiation (Well/Moderate/Poorly) 1/26/5 13/52/11 .140
BCLC (A/B) 14/18 58/18 .001
Viral hepatitis (Negative/HBV/HCV) 1/29/2 3/69/4 .960
Cirrhosis (Present/Absent) 27/5 64/12 .983
Ln (AFP) * 5.56±3.37 3.29±2.48 .001
Ln (GGT) * 3.95±0.79 3.87±0.71 .569
* Ln (natural logarithms): the primitive value of AFP and GGT was skew distribution in the groups, the
logarithmic transformation was performed to make the value fitted Gaussian distribution.
Figure 1.Microvascular invasion (MVI) was associated with relapse
free survival.
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envelope invasion (P = .003 and P = .011, respectively). No
significant association was found between miR-125b and other
clinic-pathological features, such as the patient’s age, gender, tumor
size, tumor multiplicity, histological grade and BCLC stage, viral
hepatitis, cirrhosis, AFP and GGT (P N .05).
MVI was Associated With Relapse Free Survival of
PostOperative HCC Patients
As shown in Table 2, association of MVI and the other clinical
parameters were analyzed with univariate analysis. Tumor size, BCLC
stage, AFP and envelop invasion were significantly associated with MVI,
whereas other features, including age at diagnosis, gender, differentiation,
tumor multiplicity, cirrhosis, viral hepatitis and GGT were not.
According to the presence or absence of MVI, 108 HCC patients
were divided into two groups. The Kaplan-Meier curves of relapse free
survival (RFS) according MVI was plotted in Figure 1, the group of
patients without MVI had a longer RFS than the group with MVI, the
median RFS was 9.07month and 30.73month, respectively (P = .000).
The Prognostic Value of the Width of the Surgical Margin in
HCC Patients
As shown in Figure 2A, 57 patients had a wide surgical margin
(N10 mm), 51 patients had a narrow surgical margin (≤10 mm)based on a microscopic examination. The surgical margin width
was significantly different between the groups (15.61 ± 3.5 mm vs.
2.61 ± 2.15 mm). The median relapse-free survival time in patients
with a wide surgical margin (N10 mm) and a narrow surgical margin
(≤10 mm) were 30.73 months and 22.97 months, respectively. There
was no significant difference among the groups (P = .129, Figure 2B).
The Kaplan-Meier curves were also used to analyze the association of
the surgical margin width and RFS in the subgroup of patients with or
without MVI, respectively. As shown in Figure 2C and D, a wide
surgical margin status provided a favorable RFS time in the patients
withMVI: the median relapse-free survival time for the narrow (n = 15)
and the wide (n = 17) margin groups were 8.03 months and 16.50
months, respectively. The difference was significant (P = .007,
Figure 2C). On the other hand, the surgical margin status did not
influence the RFS in patients without MVI: the median relapse-free
survival time for the narrow (n = 36) and the wide (n = 40) margin
groups were 33.67 months and 30.73 months, respectively. The
differencewas not significant (P = .761, Figure 2D).Our results revealed
that surgical margin width was associated with postoperative relapse free
survival in MVI present HCC patients, but not associated with
postoperative relapse free survival in MVI absent HCC patients.
Figure 2. Association of the width of the surgical margin and relapse free survival by Kaplan-Meier curves and the log-rank test. A,
According to the surgical margin width, the case number in each subgroup was showed in the table. B, 108 patients with narrow surgical
margin (NSM) or wide surgical margin (WSM). C, In the subgroup of HCC patients without MVI, patients with narrow surgical margin or
wide surgical margin. D, In the subgroup of HCC patients with MVI, patients with narrow surgical margin or wide surgical margin. MVI:
microvascular invasion. NSM: narrow surgical margin. WSM: wide surgical margin.
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of Preoperative HCC Patients
As positive postoperative MVI is a strong predictor of recurrence for
HCC patients after resection, we wanted to identify pre-operative
factors that are independently associated with MVI. Multivariate
analysis revealed that miR-125b, AFP and tumor size were the
independent predictive factors associated with MVI (Table 3). Then,
the discriminative power of these factors in predicting MVI of HCC
patients before operation was verified. To evaluate the predictive value,
the ROC curve was used to analyze the sensitivity and specificity. As
shown in Figure 3, the ROC curve of miR-125b showed an AUC of
76.97% (87.50% sensitivity and 51.32% specificity), which was almost
equal to the classifier established by combination of AFP and tumor size(78.82% probability, 84.21% sensitivity and 65.63% specificity).
Furthermore, the combination of AFP, MVI and miR-125b yielded a
ROC curve area of 86.68% (84.38% sensitivity and 72.37%
specificity). The results demonstrated that the combination of AFP,
MVI and miR-125b was a much more powerful discrimination tool in
predicting MVI of HCC patients before they received operation.
Discussion
Many risk factors may contribute to the postoperative recurrence,
including AFP, satellite nodal, tumor size, MVI and TNM stage [19].
Among them, the presence of MVI has been reported to be the most
significant independent risk factor affecting relapse-free survival
following curative resection and/or liver transplantation [20–23], the
Table 3. Univariate and Multivariate Cox Proportional Hazards Regression Analysis of MVI in
Relation to miR-125b and Clinical Parameters of 108 HCC Patients
Variable Logistic
Univariate Analysis Multivariate Analysis
HR (95%CI) P Value HR (95%CI) P Value
miR-125b 0.409 (0.263-0.635) .000 0.371 (0.211-0.654) .001
Tumor size 1.449 (1.193-1.761) .000 1.522 (1.181-1.960) .001
AFP 1.301 (1.121-1.510) .001 1.348 (1.104-1.645) .003
Envelope invasion 4.568 (1.688-12.356) .003
BCLC 4.143 (1.725-9.949) .001
Differentiation 1.743 (0.778-3.902) .177
GGT 1.181 (0.670-2.081) .566
Hepatitis 1.216 (0.313-4.717) .778
Cirrhosis 1.012 (0.325-3.154) .983
Tumor multiplicity 0.879 (0.218-3.553) .857
Gender 0.894 (0.307-2.606) .838
Age 1.002 (0.966-1.039) .923
Figure 3. Receiver operating characteristic curve analysis for
predicting the presence of microvascular invasion of HCC patients
preoperatively. ROC curves for the combination of tumor size and
AFP,miR-125b and the combination of tumor size, AFP andmiR-125b
in total 108 patients, respectively. The sensitivity, specificity and AUC
were indicated below the ROC graph.
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study, the RFS rates at 1 year for HCC patients with or without MVI
were 62.5% (20/32) and 13.2% (10/76), respectively, which are
consistent with the previous study [24]. Our data combined with the
results of other studies indicated that MVI in HCC patients could
provide a more consistent and reliable prediction of poor prognosis.
In addition, the invasion of the microvasculature is regarded as the
main way to spread cancer cells both in the hepatic circulation and the
systemic circulation before liver resection and/or liver transplantation in
patients with MVI [25]. And, the incidence of MVI was closely related
to the distance from the tumor capsule of the primary HCC [26]. A
previous study concluded that MVI was found beyond 1 cm from the
tumor capsule of the primary tumor in only a few HCC patients [5].
Accordingly, a more than 1-cm resection margin might be adequate for
the majority of patients to reduce tumor recurrence. However,
preserving non-tumorous liver parenchyma is also an important
consideration, especially in cirrhotic liver, for decreasing the incidence
of postoperative liver failure and improving the chance of performing
multidiscipline-team treatment in case of tumor recurrence. A recent
study demonstrated anatomic resection could achieve better survival
than non-anatomic resection in HCC patients with MVI [23]. On the
contrary, anatomic resection and non-anatomic resection brought
similar survival in patients without MVI, whereas non-anatomic
resection could preserve more remnants liver [24]. In this cohort, the
RFS of the widemargin groupwas better than the narrowmargin group,
but the differences did not reached statistical significance (P = .129).
However, the RFS for patients with MVI was significantly better in the
wide margin group than the narrow margin group, despite the small
sample size (wide/narrow, 17/15). The result implied that a wide
surgical margin is more advantageous for HCC patients with MVI. On
the other hand, the RFS for patients without MVI was no significant
difference between the wide and narrow margin group, implying that a
narrow resection margin could be benefit for HCC patients without
MVI and could preserve as much non-tumorous liver parenchyma as
possible. All of these indicated that the subgroup of HCC patients with
or without MVI can benefit from different surgical approach.
Since MVI is a histopathologic diagnosis, surgical specimens
examination is still the only accurate method for assessing MVI until
now [27]. It cannot be confirmed prior to the surgery. This naturally leads
to questions about how to identify the existence of MVI preoperatively.
Although previous studies showed that diffusion-weighted imaging
(DWI) of MR was useful in predicting MVI for HCCs [28] andinfiltrative tumor margin in CT scan had a significant correlation with
MVI [29], detection of MVI using preoperative radiological imaging still
remains a difficulty even using the latest imaging procedures, such as
ultrasonography, CT and MRI. Some other studies demonstrated that
tumor size and high AFP level [8,30], and histological grade [31] were
associated with higher rates of MVI, but using clinical data to identify
MVI accurately is also far from satisfaction. In our study, tumor size and
preoperative AFP level were independent risk factor associated withMVI,
which are consistent with previous reports. But the predictive accuracy
and efficiency of these two factors was dissatisfaction. In recent years,
miRNAs have been proposed as novel diagnostic tools for classification
and prognostic stratification of HCC. Here, when a third parameter,
serum miR-125b, was added to the classifier that established by
combined tumor size and AFP to predict MVI preoperatively, the
probability was further improved from 78.82% to 86.68%. The results
demonstrated that the combination of tumor size, AFP and miR-125b
was a much more powerful discrimination tool in predicting MVI
preoperatively and may provide clinicians with an opportunity to make a
more accurate predictive diagnosis of MVI.
In summary, given the fact that MVI has a pivotal impact on
recurrence and surgery plan selection of HCC patients, determining
an accurate preoperative prediction of MVI is essential needed. Our
study found that the combined classifier of tumor size, serum
miR-125b and preoperative AFP level is a reliable tool with sufficient
accuracy in predicting MVI in HCC patients before they received
hepatic resection. But the results of our study have some limitations
172 Preoperation Serum miR-125b in Predicting the Presence of MVI in HCC Liu et al. Translational Oncology Vol. 9, No. 3, 2016due to its retrospective, single-center design and limited sample size.
More randomized controlled trails with a large sample size are needed
to further confirm the results.
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